Navigation Links
Orexigen(R) Therapeutics Schedules May 10, 2010 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2010
Date:5/6/2010

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce its financial results for the first quarter ended March 31, 2010 on Monday, May 10th after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.

Orexigen management will host a call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (800) 573-4752 (domestic) or (617) 224-4324 (international), participant code 75892043. The webcast can be accessed live on the investor relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials and the Company has submitted a New Drug Application to the FDA.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors
2. Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R)
3. Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
4. Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009
5. Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
6. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
7. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
8. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
9. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
10. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
11. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)... Minn. , May 23, 2013  MGC Diagnostics ... a global medical technology company, today scheduled a conference ... quarter of fiscal year 2013, ended April 30, 2013. ... Thursday, May 30, 2013. The Company will report financial ... after the markets close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly ... property developed and owned by Hadassah University Hospital, ... center, today announced that its portfolio company, Cell ... Israeli Ministry of Industry and Commerce, Office of ... and advance clinical trials. Cell Cure,s development budget ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... The SCOOTER Store today announced a major milestone, saying it has ... power wheelchair to Earvin Thompson of Houston, Texas . ... leading provider of power mobility equipment, will enjoy more freedom and independence ... , ...
... GRONINGEN, The Netherlands , June 22, 2010 ... announced this week that in collaboration,with the University ... for the treatment of inhalation anthrax. In a rabbit ... time to treatment (48h post,infection) with a combination of ...
Cached Medicine Technology:The SCOOTER Store Marks Half-Millionth Life Changed 2The SCOOTER Store Marks Half-Millionth Life Changed 3The SCOOTER Store Marks Half-Millionth Life Changed 4Survival Rate Up to 100% for Late Stage Treatment of Anthrax Infections 2
(Date:5/24/2013)... -- Drugs commonly used to treat glaucoma may cause ... with vision, according to a new study. The ... to reduce eye pressure, have already been shown to ... the researchers said, suggesting that the new findings could ... should be conservative when prescribing these drugs, the researchers ...
(Date:5/24/2013)... Lake City, Utah (PRWEB) May 24, 2013 ... 2.0 , with exciting new enhancements for instructors and ... students stay more focused through personalize learning plan templates, ... new AnatomyOne release provides 500 new assessment questions, 5,000 ... and review notes. , AnatomyOne 2.0 is ...
(Date:5/24/2013)... BestSatelliteProviders.com the online satellite TV and ... compare the features and services offered by leading ... the rankings of the best rural Internet ... on their website. , BestSatelliteProviders.com – ... Matthews, the spokesperson for BestSatelliteProviders.com, “When consumers were ...
(Date:5/24/2013)... to the National Institutes of Health, Stevens Johnson Syndrome (SJS) ... the skin and mucous membranes. SJS occurs most commonly ... (i). In the early stages SJS presents flu-like symptoms, ... it affects the mucous membranes such as the eyes, mouth ... eye causes conjunctivitis (pink eye). Inflammation of the mouth ...
(Date:5/24/2013)... News) -- The number of U.S. patients admitted ... in an emergency room has increased by nearly ... study, conducted by researchers at the George Washington ... in Washington, D.C., found that patients wait five ... being admitted to the ICU. The researchers said ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2
... The Diversified Agency Services (DAS),unit of Omnicom ... position of,Executive Vice President and Director of ... will direct the client-centric and,brand-centric teams within ... resource of specialist agencies that support,the strategic ...
... is ,good news, for postmenopausal women taking anastrozole ... to previous study results, the cancer prevention drug ... cognitive performance, a new study found. , ... tamoxifen in preventing breast cancer recurrence in postmenopausal ...
... WINSTON-SALEM, N.C. Scientists at Wake Forest University School ... cancer gene called HNF1B have found a second independent ... increasing the number of genetic variants that may ... comparing the newly-discovered site with a previously discovered site ...
... , The guidelines are developed through a rigorous ... the field and a review committee of 21 international ... the first time both acute and chronic heart failure. ... patients with acute heart failure often develop chronic problems ...
... largest multi-institutional study to date examining the impact of ... individuals with suspected recurrent colorectal cancer, researchers found that ... patients, according to an article in the September issue ... The study was conducted at four sites throughout Australia ...
... Dr. Charmaine Yoest,President and CEO of Americans United ... that the daughter of McCain running mate,Sarah Palin is ... know this situation is not the ideal,Sarah Palin wished ... life,s,challenges is the true testament to our character. The ...
Cached Medicine News:Health News:Sharon Callahan Joins Diversified Agency Services Unit of Omnicom Group 2Health News:Breast Cancer Drug Not Tied to Cognitive Decline: Study 2Health News:Scientists find second site for prostate cancer gene 2Health News:PET scans lead to treatment changes in majority of colorectal cancer patients 2
This ENDOLOOP suture has a suture type - 0 PDSII and a 1.5 inch diameter....
This ENDOLOOP suture has a suture type - 0 Coated VICRYL and a 1.5 inch diameter....
... bring modern Data Management capabilities to the ... wide range of settings and definable options, ... the operator for identification, lot numbers, quality ... This data can then be transmitted to ...
Bartels Clostridium difficile Toxin A Enzyme Immunoassay (EIA) is intended for the qualitative detection of Clostridium difficile Toxin A in human faecal specimens as an aid in the diagnosis of Clost...
Medicine Products: